Targeting the NFIL3-MYC Axis Overcomes Therapy Resistance in High-Risk Multiple Myeloma
Researchers have identified the Notch downstream effector NFIL3 as an independent prognostic marker and therapeutic vulnerability whose inhibition with Raddeanin ...




